VLP Therapeutics, LLC (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced the appointment of Jacob Licht as Chief Operating Officer.
Richard Mason is head of J&J Innovation for the EMEA region, and identifying and investing in the most promising early-stage drug ideas outside the company is one of his key roles.
This ‘open innovation’ strategy is being pursued by all the big pharma companies – and now it’s simply a matter of who executes best on this approach.
Are you a US cyber, defense or security technology company looking to expand in the European market?
The Maryland Department of Commerce has an opportunity for you to soft land in the Hague Security Delta (HSD) — the largest security cluster of Europe — providing you with access to the full EU market.
Benefits of participating in the program:
- Access to shared office space at the HSD Campus — the national innovation centre for security in The Hague — at no cost to you.
- Mentorship from HSD, InnovationQuarter and the Dutch Chamber of Commerce.
- Greater exposure to global partners and opportunities to pursue clients.
- Support in accessing financial resources, engaging strategic partners, and refining business models for market opportunities in the EU region.
- Option to apply for Commerce’s ExportMD program to partially fund your travel and marketing costs.
The 2017 American Small Business Cybersecurity Xchange on October 12th will bring together cybersecurity thought leaders from government and industry and executives from small and edium-sized businesses (SMB) in a unique one-of-a-kind event. Cyber Crime Expert and Author Kevin Poulsen will give a keynote addressing this year’s theme, Preparing for Current and Emerging Threats. Designed exclusively for SMBs, the conference establishes a trusted forum for insights and action where attendees come to:
- Gain insights about current and emerging cybersecurity threats to their organizations
- Learn about new and upcoming regulatory, legislative, and supply chain requirements for cybersecurity
- Hear from government and industry experts about best practices and solutions to improve SMB cybersecurity
- Network with other SMB executives to promote information sharing and collaboration
- Learn about available cybersecurity tools and resources
Lentigen Technology Inc., a subsidiary of Miltenyi Biotec GmbH, announced today its acquisition of immunotherapy start-up Living Pharma, Inc. Eduardo Davila, PhD, Living Pharma Co-Founder and Chief Scientific Officer, who is also a faculty member of the University of Maryland School of Medicine (UMSOM), along with Koji Tamada, MD, PhD, UMSOM, invented Living Pharma’s anti-tag-chimeric antigen receptor (AT-CAR™) technology.
Emergent BioSolutions has agreed to acquire GlaxoSmithKline’s (GSK) anthrax monoclonal antibody, raxibacumab, for around $96m.
Raxibacumab is a fully human monoclonal antibody, which secured approval from the US Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis.
Emergent Biosystems (NYSE:EBS) inks an agreement with GlaxoSmithKline (NYSE:GSK) to acquire raxibacumab, a fully human monoclonal antibody for the treatment and prevention of inhaled anthrax, for $76M in upfront cash and up to $20M in milestones.
OpGen, Inc. (NASDAQ:OPGN) announces the closing of its previously announced public offering of 18,164,195 units at $0.40 per unit, and 6,835,805 pre-funded units at $0.39 per pre-funded unit, raising gross proceeds of approximately $10 million. The Company intends to use the net proceeds of this offering for general corporate purposes, including working capital and product development, particularly development of its rapid antibiotic resistance diagnostic product, and repayment of all outstanding bridge financing notes.
OMNITEC Solutions, Inc.’s Health Services Division will continue and expand their support of the National Institutes of Health (NIH), National Institute of Mental Health (NIMH) Data Archive (NDA) with a $38 Million firm-fixed-price contract award.
Since 2008, OMNITEC has supported the NIMH making the NDA the model for data sharing and computational science infrastructure at the NIH. Initially created to support 11 autism grants, the NDA now supports and shares data in mental health and substance use from over 800 projects, representing a public and private investment of $1.5 Billion.
We all have some preconceived ideas about the nature of entrepreneurialism. But, according to business master himself, Tony Robbins, starting a company or two does not an entrepreneur make. Financial savvy and business acumen may be enough to get a startup off the ground. But it takes a true entrepreneur to see beyond the creation of a project, propel past the daily managerial duties and take the all-important risks to achieve greatness.